Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2024-11-22 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司关于召开2024年第三季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2024 third quarter earnings explanation meeting (业绩说明会), including time, location, participation method, and contact information. It references the prior release of the 2024 Q3 report but does not contain actual financial data or detailed financial analysis itself. The document is short (1400 characters) and serves to inform investors about the upcoming earnings call event rather than presenting the earnings results. Therefore, it is best classified as a Call Transcript (CT) announcement or more precisely an Investor Presentation (IP) type since it is about an earnings explanation meeting with interactive Q&A. Given the nature of the document as a notice for an earnings explanation meeting, the most appropriate classification is Investor Presentation (IP).
2024-11-22 Chinese
奥锐特药业股份有限公司关于为全资子公司提供担保进展情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of a guarantee provided by the company to its wholly-owned subsidiary. It details the guarantee amount, the internal decision-making process, the financial status of the subsidiary, and the terms of the guarantee agreement. There is no indication that this is a full financial report, audit report, or earnings release. The document is a regulatory announcement about a financing-related guarantee activity, but it is not a direct capital raising or financing update per se. It is a formal disclosure of a guarantee arrangement, which fits best under the category of Regulatory Filings (RNS) as it does not fit other more specific categories like Capital/Financing Update (CAP) or Audit Report (AR). The document length is 2529 characters, which is relatively short and typical for an announcement rather than a full report.
2024-11-19 Chinese
奥锐特药业股份有限公司关于使用部分闲置募集资金进行现金管理进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of cash management using part of the company's idle raised funds. It details the investment in structured deposits, the amount, the investment period, the approval procedures by the board and supervisory committee, and risk disclosures. It references previous announcements and approvals related to the use of raised funds but does not contain financial statements or comprehensive financial data. The document length is 3250 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on updates about financing activities, specifically the use of raised funds for cash management and investment products. Therefore, this document fits best under the category of Capital/Financing Update (CAP).
2024-11-13 Chinese
奥锐特药业股份有限公司关于使用部分闲置募集资金进行现金管理到期赎回公告
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the use of idle raised funds for cash management and the redemption of a structured deposit product. It includes details of the transaction, dates, and amounts but does not contain financial statements or comprehensive financial data. The document is short (867 characters) and serves as an update on financing activities related to the company's raised funds. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories.
2024-11-12 Chinese
奥锐特药业股份有限公司第三届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the company's third board meeting of the ninth session, including approval of stock incentive plan conditions, adjustment of repurchase price, and approval of the 2024 third quarter report. It includes voting results and references to other announcements and reports published elsewhere. The document itself does not contain the full 2024 third quarter financial report but rather announces the board's approval of it and points to its publication on the stock exchange website and newspapers. The document length is short (1335 characters) and serves as a meeting resolution announcement rather than the report itself. According to the 'Menu vs Meal' rule, this is an announcement related to a report, not the report itself. Therefore, the appropriate classification is Board/Management Information (MANG), as it concerns board meeting resolutions and management decisions.
2024-10-24 Chinese
奥锐特药业股份有限公司第三届董事会第一次独立董事专门会议决议
Board/Management Information Classification · 95% confidence The document is a resolution from the independent directors of the company's board regarding specific internal matters related to the company's 2022 restricted stock incentive plan, including approval of unlocking conditions and adjustment of repurchase price. It is a formal board/management announcement about internal governance decisions rather than a full report or financial statement. The document is short (1147 characters) and focuses on board meeting resolutions, fitting the category of Board/Management Information (MANG).
2024-10-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.